A phase 1/2 trial of an investigational treatment in advanced solid tumours, run by CAS Lamvac Biotech Co., Ltd., now recruiting.
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT04165590 by CAS Lamvac Biotech Co., Ltd., with 60 participants planned, started 2019-10-24 and due to reach its primary completion in 2024-04-30.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.